Heterotopic autotransplantation of cryobanked human ovarian tissue as a strategy to restore ovarian function

Kim, S. Samuel; Hwang, In Tak; Lee, Hoi Chang

doi:10.1016/j.fertnstert.2004.02.137

Cited by 122 publications

(58 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Before the start of treatment of nonHodgkin lymphoma, Kim et al performed xenotransplantation of human ovarian tissue in experimental animals. They could not demonstrate any recurrence of lymphoma [29]. Despite all of these observations this could not be unambiguously demonstrated in other tumour types.…”

Section: Safety Of Cryopreservation Of Ovarian Tissue -The Problem Ofmentioning

confidence: 80%

See 1 more Smart Citation

Procedures for fertility preservation in female cancer patients

Langmár¹,

Iványi²,

Bánhidy³

et al. 2009

Clinical and Experimental Medical Journal

View full text Add to dashboard Cite

n REVIEWS n Modern anticancer drugs and novel oncotherapeutic methods have resulted in increasingly better survival rates and quality of life. However, this therapeutic success has been accompanied by the loss of fertility and premature menopause in many women cured of their disease. Consequently, efforts to preserve reproductive functions are of increasing importance [1][2][3][4][5][6]. The significance of such research is further emphasized by current statistical data showing that approximately one in 700 adults is a survivor of a certain childhood malignant disease. It is estimated that by the year 2010 this proportion will significantly increase and almost one in 250 adults will suffer from the late negative consequences of treatments of childhood cancer, includ-

show abstract

Section: Safety Of Cryopreservation Of Ovarian Tissue -The Problem Ofmentioning

confidence: 80%

“…A healthy girl was born at term [28]. However, some critical remarks have been made on the work of Donnez et al, because there is no unambiguous evidence whether the fertilized oocyte comes really from the transplanted ovarian tissue or from the remaining ovaries [5,14,[29][30].…”

Section: Cryopreservation Of Ovarian Tissuementioning

confidence: 99%

Procedures for fertility preservation in female cancer patients

Langmár¹,

Iványi²,

Bánhidy³

et al. 2009

Clinical and Experimental Medical Journal

View full text Add to dashboard Cite

show abstract

“…The reestablishment of endocrine functions as well as ooctye retrieval after heterotopic transplantation of human ovarian tissue has been demonstrated by several investigators (98)(99)(100)(101)(102). Nevertheless, the future of this procedure is uncertain, and, to date, no baby has been born after heterotopic transplantation.…”

Section: Cryopreservation Of Ovarian Tissuementioning

confidence: 99%

Breast cancer and fertility preservation

Fabian¹,

Klemp²

2011

Principles and Practice of Fertility Preservation

View full text Add to dashboard Cite

Objective-To review the benefits of adjuvant systemic therapy given to women with breast cancer of reproductive age, its effects on fertility, and options for fertility preservation.Design-Publications relevant to fertility preservation and breast cancer were identified through a PubMed database search. Conclusion(s)-Mostwomen who develop invasive breast cancer under age 40 will be advised to undergo adjuvant chemotherapy with or without extended antihormonal therapy to reduce the risk of recurrence and death from breast cancer. Adjuvant chemotherapy particularly with alkylating agents such as cyclophosphamide is gonadotoxic and markedly accelerates the rate of age-related ovarian follicle loss. Although loss of fertility is an important issue for young cancer survivors, there is often little discussion about fertility preservation before initiation of adjuvant therapy. Greater familiarity with prognosis and effects of different types of adjuvant therapy on the part of infertility specialists and fertility preservation options such cryopreservation of embryos, oocytes, and ovarian tissue on the part of oncologists would facilitate these discussions. Establishment of rapid fertility consultation links within cancer survivorship programs can help ensure that every young woman who is likely to undergo gonadotoxic cancer treatment is counseled about the effects of therapy and options available to her to increase the likelihood of childbearing after cancer treatment. KeywordsBreast cancer; fertility preservation; embryo cryopreservation; oocyte cryopreservation; ovarian tissue cryopreservation; ovarian transplantation; GnRH agonist; chemotherapy; cancer survivorshipIn the United States, 5%-7% of cases of invasive breast cancer (~11,000/year) occur in women who are under age 40 at diagnosis (www.seer.cancer.gov.2008), most between the ages of 30 and 40 (1). As almost one quarter of first live births in the United States occur between the ages of 30 and 40, many of these women will not have had the opportunity to bear a child (2). Less than 10% of women who develop invasive breast cancer under age 40 have children postdiagnosis (3-5), despite survey results suggesting about half desire to do so (6) and observational studies that do not indicate an increased risk of relapse or death for women who become pregnant after a breast cancer diagnosis (7-9). Receipt of cytotoxic chemotherapy is a major factor in the low rate of live births after a diagnosis of breast

show abstract

“…The lower surgical burden of heterotopic transplants is attractive, because they involve a more superficial procedure where they can be monitored readily and oocytes can be aspirated for IVF (Kim et al 2004, Oktay et al 2004. To date, only early cleavage stages and a biochemical pregnancy have been attained using this strategy (Oktay et al 2004, Rosendahl et al 2006, although the generation of a baby monkey from an oocyte matured in a subcutaneous graft of fresh tissue bodes well for eventual success in humans .…”

Section: Fertility Preservationmentioning

confidence: 99%

Ovary and uterus transplantation

Gosden

2008

Reproduction

View full text Add to dashboard Cite

Ovarian and uterine transplantation are procedures gaining more attention again because of potential applications in respectively fertility preservation for cancer and other patients and, more tentatively, women with uterine agenesis or hysterectomy. Cryopreservation of tissue slices, and possibly whole organs, is providing opportunities for banking ovaries for indefinite periods before transplanting them back to restore fertility. The natural plasticity of this organ facilitates grafting to different sites where they can be revascularized and rapidly restore the normal physiology of secretion and ovulation. Ischemic damage is a chief limitation because many follicles are lost, at least in avascular grafts, and functional longevity is reduced. Nevertheless, grafts of young ovarian tissue, even after cryopreservation, can be highly fertile in laboratory rodents and, in humans, autografts have functioned for up to 3 years before needing replacement. Transplantation by vascular anastomosis provides potentially longer function but it is technically much more demanding and riskier for the recipient. It is the only practicable method with the uterus, and has enabled successful pregnancies in several species, but not yet in humans. Contrary to claims made many years ago, neither organ is privileged immunologically, and allografts become rapidly rejected except in hosts whose immune system is deficient or suppressed pharmacologically. All in all, transplantation of these organs, especially the ovary, provides a broad platform of opportunities for research and new applications in reproductive medicine and conservation biology.

show abstract

Heterotopic autotransplantation of cryobanked human ovarian tissue as a strategy to restore ovarian function

Cited by 122 publications

References 9 publications

Procedures for fertility preservation in female cancer patients

Procedures for fertility preservation in female cancer patients

Breast cancer and fertility preservation

Ovary and uterus transplantation

Contact Info

Product

Resources

About